Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633793 | 0.88 | KDM4E (0.54) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL7724076 | 0.87 | KDM4E (0.51) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL5228001 | 0.87 | ALDH1A1 (0.52) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL1051606 | 0.83 | KDM4E (0.53) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL4028821 | 0.83 | KDM4E (0.53) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL12522017 | 0.83 | KDM4E (0.53) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL12447266 | 0.79 | ALDH1A1 (0.53) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL5103108 | 0.79 | KDM4E (0.50) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL5800641 | 0.79 | KDM4E (0.50) | HSD17B10KDM4EMEN1POLBKMT2A | |
| SCHEMBL5023939 | 0.79 | PPARA (0.52) | HSD17B10KDM4EMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | HSD17B10 1053/4885KDM4E 4614/4885MEN1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.